Spots Global Cancer Trial Database for natural killer cell
Every month we try and update this database with for natural killer cell cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma | NCT01238159 | Extranodal NK-T... | CCRT+MIDLE chem... | 18 Years - | Samsung Medical Center | |
| Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell ("SMT-NK") Cell Therapy in Advanced Biliary Tract Cancer | NCT03358849 | Advanced Biliar... | Natural killer ... | 18 Years - 75 Years | Yonsei University | |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | NCT04464967 | Advanced Solid ... Metastatic Canc... HER2-positive B... HER2-positive G... HER-2 Protein O... Esophageal Canc... Ovarian Cancer Endometrium Can... Bladder Cancer Pancreatic Canc... Colorectal Canc... Non Small Cell ... EGF-R Positive ... Head and Neck S... Triple Negative... Cervical Cancer Sarcoma | SNK01 Trastuzumab Cetuximab | 18 Years - 75 Years | NKGen Biotech, Inc. | |
| The Change of NK Cell Activity After Head and Neck Cancer Surgery | NCT02661776 | The Patients Un... | 19 Years - | Yonsei University | ||
| Phase I Study of Combined Immune Cell Therapy in Patients With Stage 4 Colorectal Cancer With Metastatic Lesion Who Failed Prior Standard of Care | NCT06296056 | Colorectal Canc... Metastatic Colo... | Combi | 19 Years - | Seoul Hospital | |
| Haploidentical NK-cell Infusion in Acute Myeloid Leukemia | NCT01947322 | Acute Myeloid L... | Allogenic NK ce... | 18 Years - 65 Years | Assistance Publique - Hôpitaux de Paris | |
| Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma | NCT00698009 | Neuroblastoma | Fludarabine Cyclophosphamid... Natural Killer ... Mesna Interleukin-2 | - | M.D. Anderson Cancer Center | |
| Haploidentical NK-cell Infusion in Acute Myeloid Leukemia | NCT01947322 | Acute Myeloid L... | Allogenic NK ce... | 18 Years - 65 Years | Assistance Publique - Hôpitaux de Paris | |
| A Study to Assess AFM13 in Patients With Hodgkin Lymphoma | NCT01221571 | Hodgkin Lymphom... | AFM 13 | 18 Years - | Affimed GmbH | |
| Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients | NCT00846157 | Diffuse Large B... | NKM injection | 20 Years - 70 Years | NKBio Co.Ltd. | |
| Quadruple Immunotherapy for Neuroblastoma | NCT05754684 | Neuroblastoma R... | Natural killer ... Dinutuximab bet... Interleukin-2 Granulocyte-Mac... Spironolactone Naxitamab | - 18 Years | Hong Kong Children's Hospital | |
| Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy | NCT03941262 | Refractory Canc... Metastatic Canc... Recurrent Cance... Unresectable Ca... Solid Tumor, Ad... Advanced Cancer Advanced Solid ... | SNK01 Avelumab Pembrolizumab | 18 Years - 75 Years | NKGen Biotech, Inc. | |
| Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma | NCT06044506 | Hepatocellular ... | Autologous Natu... Clinimacs Plus | 20 Years - 60 Years | Dr Cipto Mangunkusumo General Hospital | |
| Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | NCT02890758 | Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Chronic Myeloid... Chronic Lymphoc... Non Hodgkin Lym... Hodgkin Lymphom... Myeloproliferat... Plasma Cell Mye... Colon Carcinoma Adenocarcinoma ... Soft Tissue Sar... Ewing's Sarcoma Rhabdomyosarcom... | Natural Killer ... ALT803 | 18 Years - | Case Comprehensive Cancer Center | |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | NCT04464967 | Advanced Solid ... Metastatic Canc... HER2-positive B... HER2-positive G... HER-2 Protein O... Esophageal Canc... Ovarian Cancer Endometrium Can... Bladder Cancer Pancreatic Canc... Colorectal Canc... Non Small Cell ... EGF-R Positive ... Head and Neck S... Triple Negative... Cervical Cancer Sarcoma | SNK01 Trastuzumab Cetuximab | 18 Years - 75 Years | NKGen Biotech, Inc. | |
| Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell ("SMT-NK") Cell Therapy in Advanced Biliary Tract Cancer | NCT03358849 | Advanced Biliar... | Natural killer ... | 18 Years - 75 Years | Yonsei University | |
| Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | NCT05099549 | Squamous Cell C... Carcinoma, Non-... Colorectal Neop... Advanced Solid ... Refractory Tumo... Metastatic Tumo... | AFM24 SNK01 | 18 Years - | NKGen Biotech, Inc. | |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | NCT04464967 | Advanced Solid ... Metastatic Canc... HER2-positive B... HER2-positive G... HER-2 Protein O... Esophageal Canc... Ovarian Cancer Endometrium Can... Bladder Cancer Pancreatic Canc... Colorectal Canc... Non Small Cell ... EGF-R Positive ... Head and Neck S... Triple Negative... Cervical Cancer Sarcoma | SNK01 Trastuzumab Cetuximab | 18 Years - 75 Years | NKGen Biotech, Inc. | |
| Effects of Anesthetic Technique on NK Cells | NCT02669186 | Pain Anesthesia Cancer | Bupivacaine + F... Bupivacaine | 18 Years - 80 Years | Cedars-Sinai Medical Center | |
| Quadruple Immunotherapy for Neuroblastoma | NCT05754684 | Neuroblastoma R... | Natural killer ... Dinutuximab bet... Interleukin-2 Granulocyte-Mac... Spironolactone Naxitamab | - 18 Years | Hong Kong Children's Hospital | |
| Effects of Anesthetic Technique on NK Cells | NCT02669186 | Pain Anesthesia Cancer | Bupivacaine + F... Bupivacaine | 18 Years - 80 Years | Cedars-Sinai Medical Center | |
| A Study to Assess AFM13 in Patients With Hodgkin Lymphoma | NCT01221571 | Hodgkin Lymphom... | AFM 13 | 18 Years - | Affimed GmbH | |
| Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | NCT05099549 | Squamous Cell C... Carcinoma, Non-... Colorectal Neop... Advanced Solid ... Refractory Tumo... Metastatic Tumo... | AFM24 SNK01 | 18 Years - | NKGen Biotech, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
